ArticleFrontiers in molecular biosciences2020
CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus.
Article in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis.World journal of surgical oncology · 2022Pooled it
- Prognostic value of TIGIT in East Asian patients with solid cancers: A systematic review, meta-analysis and pancancer analysis.Frontiers in immunology · 2022Pooled it
- Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis.Journal of immunology research · 2021Pooled it
- The tumor-microenvironment-associated prognostic gene TIGIT promotes malignant phenotypes in esophageal carcinoma.Translational oncology · 2026Article
- Esophageal Small Cell Carcinoma: From Bench Discoveries to Bedside Therapeutics.International journal of biological sciences · 2026Review
- Prognostic and Predictive Significance of B7-H3 and CD155 Expression in Gastric Cancer Patients.Diagnostics (Basel, Switzerland) · 2025Article
- NSE and ProGRP Are Promising Markers for Diagnosis, Efficacy Evaluation, Follow-Up Monitoring, and Prognosis of Small Cell Esophageal Carcinoma.Thoracic cancer · 2025Article
- Integrated bioinformatics analysis to explore potential therapeutic targets and drugs for small cell carcinoma of the esophagus.Frontiers in bioinformatics · 2025Article
- Development and validation of a prognostic model for overall survival in small cell carcinoma of the esophagus.Frontiers in oncology · 2025Article
- The Functional and Prognostic Impact of TIGIT Expression on Bone Marrow NK Cells in Core Binding Factor-Acute Myeloid Leukemia Patients at Diagnosis.Biomedicines · 2024Article
- Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy.Cancers · 2024Review
- Mechanisms of tumor immunosuppressive microenvironment formation in esophageal cancer.World journal of gastroenterology · 2024Review
- MGMT unmethylation and high levels of CD47 and TIGIT indicate a poor prognosis in adult diffuse gliomas.Frontiers in immunology · 2024Article
- The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.Frontiers in immunology · 2024Review
- TIGIT in Lung Cancer: Potential Theranostic Implications.Life (Basel, Switzerland) · 2023Review
- CD155 is a putative therapeutic target in medulloblastoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- The Features of Checkpoint Receptor-Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition.Biomedicines · 2022Review
- PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma.Biomedicines · 2022Article
- Immune checkpoint CD155 promoter methylation profiling reveals cancer-associated behaviors within breast neoplasia.Cancer immunology, immunotherapy : CII · 2022Article
- Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD155/TIGIT overexpression has been detected in various human malignancies; however, its expression status in primary small cell carcinoma of the esophagus (PSCCE) and its prognostic significance remain unclear. In this study, we aimed to explore the expression and prognostic value of CD155 and TIGIT in PSCCE. We detected CD155 and TIGIT expression in 114 cases of PSCCE using immunohistochemistry (IHC) and evaluated their relationship with the clinicopathological characteristics and survival of the patients. Survival analyses were performed using the Kaplan-Meier method and Cox proportional hazards model. Nomogram performance was assessed via the concordance index (C-index) and calibration plots. Decision curve analysis (DCA) was performed to evaluate the net benefit of the nomogram. We found that CD155 and TIGIT were overexpressed in PSCCE tissues, CD155 expression correlated positively with TIGIT (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.